Leuprolide Dosage

Medically reviewed on March 5, 2018.

Usual Adult Dose for Prostate Cancer

1 mg injection subcutaneously once a day or
7.5 mg depot IM or depot subcutaneously once a month or
22.5 mg depot IM once every 3 months or
30 mg depot IM once every 4 months or
45 mg subcutaneous injection every 6 months or
65 mg subcutaneous implant once every 12 months

Use: Palliative treatment of advanced prostate cancer

Usual Adult Dose for Endometriosis

3.75 mg IM once a month for up to 6 months or 11.25 mg depot every 3 months

Comments:
-In women receiving leuprorelin for endometriosis, hormone replacement therapy is recommended to reduce bone mineral density loss and vasomotor symptoms. The risks and benefits of each therapy should be considered.

Uses: Management of endometriosis (including pain relief and reduction of endometriotic lesions), preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata

Usual Adult Dose for Uterine Leiomyomata

3.75 mg IM once a month for up to 6 months or 11.25 mg depot every 3 months

Comments:
-In women receiving leuprorelin for endometriosis, hormone replacement therapy is recommended to reduce bone mineral density loss and vasomotor symptoms. The risks and benefits of each therapy should be considered.

Uses: Management of endometriosis (including pain relief and reduction of endometriotic lesions), preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata

Usual Pediatric Dose for Precocious Puberty

Depot injection:
Body weight: Less than or equal to 25 kg: 7.5 mg IM once a month
Body weight: Greater than 25 kg to 37.5 kg: 11.25 mg IM once a month
Body weight: Greater than 37.5 kg: 15 mg IM once a month

Comments:
-Hormonal levels should be tested after 1 to 2 months of therapy and with each dose change to ensure adequate pituitary gonadotropin suppression.
-Once a dose that results in adequate hormonal suppression, it can often be maintained for the duration of therapy in most children; however, hormonal suppression should be verified as weight can increase significantly while on therapy.

Subcutaneous Injection:
Initial dose: 50 mcg/kg/day subcutaneously. If total downregulation is not achieved, the dose should be titrated upward by 10 mcg/kg/day. This dose will be considered the maintenance dose.

Comments:
-The dosage should be adjusted for weight changes.
-Discontinuation of therapy be considered before age 11 for females and before age 12 for males.

Use: Treatment of children with central precocious puberty (CPP)

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

-Pediatric patients: If adequate hormonal and clinical suppression is not reached with the starting dose, it should be increased to the next available higher dose (e.g. 11.25 mg or 15 mg at the next monthly injection).

Precautions

Safety and efficacy have not been established in patients younger than 2 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-The injection site should be varied periodically.
-Avoid areas with brawny or fibrous subcutaneous tissue or locations that could be rubbed or compressed (e.g., with a belt or clothing waistband)

Storage requirements:
-The manufacturer product information should be consulted.

Reconstitution/preparation techniques:
-The manufacturer product information should be consulted.

Monitoring:
-Metabolic: Blood glucose and/or glycosylated hemoglobin (HbA1c) periodically

Patient advice:
-This drug can influence the ability to drive and use machines.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer